Market Capitalization (Millions $) |
519 |
Shares
Outstanding (Millions) |
35 |
Employees |
- |
Revenues (TTM) (Millions $) |
95 |
Net Income (TTM) (Millions $) |
-29 |
Cash Flow (TTM) (Millions $) |
9 |
Capital Exp. (TTM) (Millions $) |
0 |
Aveo Pharmaceuticals Inc
Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing targeted cancer therapies. The company primarily focuses on developing medicines that inhibit the growth and spread of tumors and improve patients' outcomes. Their primary product candidate is tivozanib, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, which is being developed as a treatment for advanced renal cell carcinoma and other types of cancer. Aveo Pharmaceuticals Inc is committed to advancing their pipeline of innovative therapies to address unmet medical needs.
Company Address: 30 Winter Street Boston 2108 MA
Company Phone Number: 400-0101 Stock Exchange / Ticker: AVEO
|